|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||486.43 g·mol−1|
|3D model (JSmol)|
Vilanterol (INN, USAN) is an ultra-long-acting β2 adrenoreceptor agonist (ultra-LABA), which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD).. The combination is also approved for the treatment of asthma in Europe, Japan and New Zealand.
Vilanterol is available in following combinations: